Senores Pharmaceuticals Limited (SPL), through its wholly-owned US subsidiary, Senores Pharmaceuticals, Inc. (SPI), has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Tramadol Tablets from APDM Pharmaceuticals Private Limited (APDM).
Tramadol is an opioid analgesic used for managing moderate to severe pain when alternative treatments are inadequate. This acquisition strengthens SPL’s position in the US generic pharmaceutical market.
According to IQVIA, the US market size for Tramadol Tablets stood at approximately USD 61.95 million for the 12 months ending December 2024. Data from Symphony, a specialty data aggregator, estimates the market at around USD 119.09 million for the 12 months ending March 2025.
The acquisition will be funded through proceeds raised by SPL’s Initial Public Offering (IPO), aligning with the objectives stated in its Red Herring Prospectus. This strategic move highlights SPL’s focus on expanding its US product portfolio and enhancing revenue growth through high-demand generic drugs.
